Jain S, Filipe M I, Gullick W J, Linehan J, Morris R W
Department of Histopathology, UMDS Guy's Hospital, London, UK.
Int J Cancer. 1991 Jul 9;48(5):668-71. doi: 10.1002/ijc.2910480506.
The c-erbB-2 proto-oncogene encodes a growth factor receptor which is over-expressed in a variety of human adenocarcinomas. Recent reports suggest that it may be of value in arriving at prognosis in breast and ovarian cancer. In this study, c-erbB-2 expression was investigated in 93 routinely processed cases of gastric carcinoma, using an immunohistochemical technique. c-erbB-2 membrane immunoreactivity was observed in 11% (10/93) of tumours, all of which were of the well differentiated intestinal type (p less than 0.01). Overall, patients with tumours expressing this proto-oncogene had a significantly improved prognosis (p less than 0.05). Within the group of intestinal-type tumours, those that were c-erbB-2-positive formed a distinct sub-population which had a better prognosis (p less than 0.02), suggesting possible differences in aetiology.
c-erbB-2原癌基因编码一种生长因子受体，该受体在多种人类腺癌中过度表达。最近的报告表明，它可能对判断乳腺癌和卵巢癌的预后有价值。在本研究中，采用免疫组织化学技术对93例常规处理的胃癌病例进行了c-erbB-2表达情况的研究。在11%（10/93）的肿瘤中观察到c-erbB-2膜免疫反应性，所有这些肿瘤均为高分化肠型（p<0.01）。总体而言，表达该原癌基因的肿瘤患者预后明显改善（p<0.05）。在肠型肿瘤组中，c-erbB-2阳性的肿瘤形成了一个具有较好预后的独特亚群（p<0.02），提示病因可能存在差异。
